↓ Skip to main content

Oncotarget

Article Metrics

Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer

Overview of attention for article published in Oncotarget, January 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#28 of 12,118)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
43 news outlets

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
30 Mendeley
Title
Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer
Published in
Oncotarget, January 2016
DOI 10.18632/oncotarget.6871
Pubmed ID
Authors

Qian Zhao, Zhongtang Wang, Wei Huang, Qiang Wang, Shuzeng Yu, Tao Zhou, Dan Han, Zhenying Wu, Heyi Gong, Hongfu Sun, Jian Zhang, Yumei Wei, Hongsheng Li, Zicheng Zhang, Haiqun Lin, Baosheng Li

Abstract

Our aim was to evaluate the efficacy and safety of cisplatin with pemtrexed or vinorelbine and concurrent late course accelerated hyperfractionated radiotherapy (LCAHRT). Patients with unresectable stage III non-small-cell lung cancer (NSCLC) were randomly assigned to two regimens. The experimental (PP) arm included cisplatin, pemtrexed and concurrent LCAHRT based on bilateral lung V20 = 33%. The control (NP) arm used cisplatin, vinorelbine with the same radiotherapy protocol. The primary endpoint was overall survival. Median survival times were 26.0 months (95% CI 23.2 to 28.7 months) and 28.5 months (95% CI 17.1 to 39.9 months) for the NP and PP arms, respectively (P = 0.26). Median progression-free survival was 12.5 months and 17.5 months in the NP and PP arms (P = 0.07). In both arms of the study, there were no differences in overall survival between patients with squamous and nonsquamous NSCLC. The incidences of grade 3 or 4 toxicity were higher in NP than PP arm. With concurrent LCAHRT, pemetrexed/cisplatin was equally as efficacious as vinorelbine/cisplatin, but showed a more favorable toxicity profile.

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 30 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 27%
Student > Master 4 13%
Student > Bachelor 3 10%
Professor 3 10%
Other 3 10%
Other 6 20%
Unknown 3 10%
Readers by discipline Count As %
Medicine and Dentistry 11 37%
Nursing and Health Professions 4 13%
Pharmacology, Toxicology and Pharmaceutical Science 2 7%
Agricultural and Biological Sciences 2 7%
Social Sciences 2 7%
Other 5 17%
Unknown 4 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 338. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2018.
All research outputs
#33,863
of 13,560,184 outputs
Outputs from Oncotarget
#28
of 12,118 outputs
Outputs of similar age
#1,707
of 268,040 outputs
Outputs of similar age from Oncotarget
#7
of 789 outputs
Altmetric has tracked 13,560,184 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,118 research outputs from this source. They receive a mean Attention Score of 3.8. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,040 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 789 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.